ISO 10993 Biocompatibility
Consulting for
Medical Devices
Medical device biocompatibility consulting for ISO 10993 BEPs, BERs, TRAs, EU MDR, FDA 510(k), and selected CDSCO submissions — built around the actual device, the available evidence, and the pathway under review.
Typical High-Priority Projects
Where teams usually need help fast
Aligned with the frameworks reviewers actually scrutinize
Built for teams that need a clear submission path, not generic template writing
I typically support teams that already have a device, a regulatory target, and a concrete documentation problem to solve.
MedTech Startups
Founders and first-time submission teams that need a defensible BEP, BER, or biocompatibility plan from scratch.
RA/QA Teams
Regulatory and quality teams that need expert support on endpoint strategy, waiver justification, or document review before submission.
Manufacturers Updating Legacy Files
Companies upgrading older BEPs and BERs to align with ISO 10993-1:2025, lifecycle framing, and current reviewer expectations.
Submission Consultants
Consultants and cross-functional teams that need specialist ISO 10993 input for FDA, EU MDR, or deficiency-response packages.
Best when these details are already clear
The clearer the starting inputs are, the faster I can assess scope, identify likely documentation gaps, and recommend the next practical step.
When those basics are defined upfront, scope review is usually faster and the work can start with fewer back-and-forth questions.
Devices I Work With
If your device touches, implants into, or communicates with the human body — I can prepare the biological evaluation documentation.
Implantable Devices
Long-term and permanent implants — the most demanding biocompatibility category requiring full endpoint coverage and genotoxicity assessment.
Wound Care & Dressings
Surface-contacting devices with intact or compromised skin contact. Biocompatibility assessment for wound care materials and dressings.
Catheters & Tubing
Short and long-term blood/tissue contact devices. Chemical characterization, extractables assessment, and TRA for polymeric materials.
Dental Devices
Oral contact devices including restorative materials, surgical instruments, and orthodontic devices requiring ISO 10993 biological evaluation.
Cardiovascular Devices
Blood-contacting devices with critical biocompatibility requirements including thrombogenicity and haemocompatibility endpoint evaluation.
Diagnostic & IVD-Adjacent
Devices that contact the patient during diagnostic procedures — biosensors, imaging probes, and electrochemical sensors. Teams working on patient-contacting sensor interfaces can also review the biosensor biocompatibility support page.
Orthopaedic Devices
Bone-contacting implants and fixation devices requiring genotoxicity, implantation, and systemic toxicity endpoint evaluation.
Ophthalmic Devices
Devices in contact with ocular tissue — a sensitive contact category requiring careful material selection and cytotoxicity evaluation.
Not sure if your device fits? Send me a brief description — I'll confirm scope and timeline within 24 hours, no obligation.
Common ISO 10993 Problems I Solve
Medical device companies face recurring biological evaluation challenges. I specialize in resolving each one.
Notified Body Query on BEP/BER
Your notified body flagged gaps in your biological evaluation plan or report. I prepare structured, scientifically justified responses.
Notified Body ResponseUncertain Which Tests to Waive
ISO 10993-1 allows test waivers with proper justification. I identify which endpoints can be justified and prepare the scientific rationale.
Test Waiver JustificationFirst Biocompatibility Assessment
MedTech startups preparing their first biological evaluation documentation. I build scientifically defensible BEPs from scratch.
Full BEP DevelopmentFDA 510(k) Section Rejected
Your biocompatibility section was rejected or flagged by FDA. I prepare FDA-aligned documentation per the FDA biocompatibility guidance (2020, updated 2023).
FDA Asked for More DataMaterial or Design Change
Device material or design change triggers a biocompatibility re-evaluation. I perform change impact assessments aligned with ISO 10993-1.
Change Impact AssessmentLegacy BER Needs Update
ISO 10993-1:2025 introduced lifecycle approach changes. I perform gap analysis and update legacy documentation to current requirements.
ISO 10993-1:2025 UpgradeISO 10993 & Regulatory Services
Core ISO 10993 drafting, gap analysis, and submission remediation for teams preparing CE Mark, FDA, and selected India pathways.
Biological Evaluation Plan (BEP)
ISO 10993-1:2018/2025 compliant endpoint strategy. Delivered in 3–5 business days.
View dedicated BEP service page Already have a draft? Use the BEP review service ISO 10993-1:2025Biological Evaluation Report (BER)
Literature evaluation, existing data assessment, risk-based conclusions. 5–7 business days.
View dedicated BER service page Already have a draft? Use the BER review service ISO 10993-1:2025Toxicological Risk Assessment (TRA)
AET/TTC calculations per ISO 10993-17 and ISO 10993-18 for extractables and leachables.
Read how TRA supports modern biological evaluation ISO 10993-17/18ISO 10993-1:2025 Gap Analysis
Assess existing BEP/BER documentation against the updated 2025 requirements. Identify and resolve gaps.
View dedicated gap-analysis page 2025 UpdateMaterial Change Biocompatibility Assessment
Structured change-impact review for supplier, formulation, coating, sterilization, process, packaging, and design changes.
View dedicated material-change page Change ControlImplantable Device Biocompatibility Support
ISO 10993 support for implantable devices, implantable biosensors, long-term endpoint strategy, and file remediation.
View dedicated implantable-device page High-risk devicesBiocompatibility Documentation Review
Best first step when a BEP, BER, TRA, or summary section already exists and needs a specialist check before submission.
Use the review as your first step Pre-submissionEU MDR Technical File — Biocompatibility Section
Annex I GSPR §10 compliant documentation for CE Mark technical file submission.
View dedicated EU MDR support page EU MDRNotified Body Query Response
Point-by-point remediation for BEP, BER, waiver, materials, and Annex I gaps raised during CE Mark review.
View dedicated notified body response page CE Mark RemediationFDA 510(k) Biocompatibility Section
Per FDA biocompatibility guidance (2020, updated 2023). Structured biocompatibility summary designed to support FDA reviewer requirements.
View dedicated FDA support page FDA 510(k)CDSCO Strategy & Documentation Support
Selected-project India support for pathway planning, documentation readiness, and biocompatibility-linked submission strategy.
View dedicated CDSCO support page Selected CDSCOBiocompatibility Documentation Review
Best first step when a draft file already exists and the team needs to know whether it is usable, weak in key places, or headed toward reviewer friction.
See how the review is packaged Pre-submissionSelected India / CDSCO support and adjacent work such as CER, PMCF/PMS, and scientific writing remain available, but the homepage stays focused on ISO 10993 documentation and submission-facing remediation. If your team already has a draft file, the review offer is usually the cleanest first step.
Real Biocompatibility Science, Not Template Writing
I have personally conducted cytotoxicity assays, worked on ISO 10993-aligned biocompatibility testing, and published research on biological evaluation endpoints for implantable biosensor systems. With 10+ years in biomaterials science and hands-on bench experience, when I write your BER, I understand the science behind each endpoint — not just the regulatory requirement.
Bench-Level Research Experience
Hands-on cytotoxicity, oxidative stress, biomaterial-cell interaction, and ISO 10993-aligned biocompatibility testing at INSERM U1026 Biotis in Bordeaux, within the Marie Skłodowska-Curie ImplantSens research network on implantable electrochemical biosensors.
ISO 10993-1:2025 Expert
Deep knowledge of the 2025 revision — lifecycle approach, explicit benefit-risk determination, test waiver justification, and legacy BEP/BER gap analysis. I build documentation designed to support first-pass review readiness.
Implantable Device Specialist
PhD research on implantable electrochemical biosensors at IIT Kanpur — covering the most demanding biocompatibility category: long-term implant contact, genotoxicity, and chronic toxicity pathways.
Fast, Structured Delivery
BEP in 3–5 business days. BER in 5–7 business days. Delivered in Word and PDF with one revision included. Available across EU, US, and Asia-Pacific time zones.
International Research & Client Experience
Lived and researched in India, France, and the EU — I understand regulatory expectations across markets. Clients served across EU, UK, US, and Asia-Pacific. Fluent in English; working knowledge of French.
Arvind Rathore
ISO 10993 Biocompatibility Consultant
From Inquiry to Delivered Documentation
A clear, structured process from first contact to submission-ready documentation.
Initial Scoping Call
We review your device, contact category, current documentation, and submission timeline so I can confirm fit and define the most practical next step.
Scope & Proposal
I define the documentation scope, endpoint strategy, and deliverables. Clear timeline and fixed price quote.
Documentation Drafting
I prepare scientifically grounded BEP/BER/TRA documentation aligned to your regulatory target (EU MDR or FDA).
Review & Delivery
You review the draft, provide feedback, and I finalize. Delivered in Word and PDF. One revision included.
Representative File Outcomes
Anonymized examples of how draft files, remediation packages, and legacy documentation were turned into cleaner, more usable submission material. Shared to illustrate fit and depth of work, not to promise identical external outcomes.
Implantable Biosensor — CE Mark Submission
Electrochemical glucose sensor for long-term subcutaneous implantation. Prepared a full BEP and BER covering 14 ISO 10993 endpoints, including genotoxicity and chronic toxicity, with documentation structured for notified body review.
Vascular Catheter — FDA Additional Information Response
FDA issued an additional information request citing incomplete cytotoxicity extract rationale and missing chemical characterization for the polymeric hub. Prepared a targeted response package with AET calculations, chemistry framing, and test-waiver justifications for reviewer follow-up.
Wound Dressing — Legacy BER Gap Analysis
MedTech startup with an existing BER prepared under ISO 10993-1:2018. Performed a gap analysis against the 2025 revision requirements and updated the core sections that needed stronger lifecycle and benefit-risk framing.
Orthopaedic Fixation Device — Toxicological Risk Assessment
Titanium-alloy bone fixation plate with polymeric coating. Performed ISO 10993-17/18 compliant TRA including coating extractables review, AET thresholds, and TTC-based justification logic for low-level compounds.
Dental Implant — EU MDR Technical File Biocompatibility Section
First-time EU MDR submission for a zirconia dental implant. Drafted the complete Annex I GSPR §10 biocompatibility section, including BEP, BER, and risk-management integration for Technical File review.
Catheter Hub Material Change — Re-evaluation Assessment
Manufacturer changed hub material from ABS to a medical-grade polycarbonate blend. Performed ISO 10993-1:2025 change impact assessment, documented the chemical-equivalence rationale, and updated the BER section for amendment readiness.
Frameworks & Standards I Work With
Biological Evaluation Series
- Part 1: Evaluation & Testing (2018 & 2025)
- Part 5: Cytotoxicity
- Part 10: Sensitization & Irritation
- Part 17: Toxicological Risk Assessment
- Part 18: Chemical Characterization
EU MDR 2017/745
- Annex I — GSPR §10 Biocompatibility
- Annex II — Technical Documentation
- Annex III — PMS Documentation
- CER (MEDDEV 2.7/1 Rev.4)
- PMCF Plan & Report
FDA 510(k) & PMA
- FDA ISO 10993 Guidance (2020)
- 510(k) Biocompatibility Section
- De Novo Submissions
- PMA Applications
- FDA Query Responses
Quality & Risk Management
- ISO 13485:2016 QMS
- ISO 14971:2019 Risk Management
- Risk-Based Biocompatibility Strategy
- Design Control Documentation
- CAPA Documentation
How to Hire Me
Three clear engagement paths. If a draft file already exists, start with the review offer. If not, pick the drafting or remediation path that matches the real problem.
Submission Gap Review
You already have a BEP, BER, TRA, or summary section and need the fastest credible first step
- Expert review of your existing BEP, BER, or TRA
- Written gap memo with specific findings
- Recommended fixes per ISO 10993-1:2025
- Regulatory alignment check (EU MDR or FDA)
- One follow-up call to discuss findings
Full Documentation Draft
You need a complete BEP, BER, or TRA written from scratch
- Full BEP or BER drafted from device brief
- All applicable ISO 10993 endpoints addressed
- Scientifically justified test waivers where applicable
- Aligned to EU MDR Annex I §10 or FDA 2020 guidance
- Delivered in Word + PDF, one revision included
Deficiency Remediation
FDA or notified body flagged your documentation — you need a targeted, fast response
- Analysis of FDA/NB deficiency letter or query
- Point-by-point written response document
- Updated BEP/BER sections where required
- Scientific justification for each deficiency
- Submission-ready format, one revision included
Share your situation and I will tell you the likely scope, the fastest practical path forward, and whether the project is a fit.
Questions teams ask before they start a scope
The fastest way to move forward is to clarify whether you need a new BEP, a document review, or a cleanup of a file that already exists.
Do we need all testing complete before a BEP is written?
No. A strong BEP usually comes first. It sets the endpoint strategy, the evidence path, and where existing data or waivers may be enough.
View BEP serviceWhat makes a BEP look generic to a reviewer?
Usually vague device framing, copied endpoint tables, and waiver logic that is asserted without a clear scientific basis tied to the actual device.
Read the BEP mistakes articleWhat if we already have a draft BEP, BER, or TRA?
That is often a review problem, not a rewrite problem. A fast gap review can show whether the file needs selective remediation or deeper restructuring.
Start with a gap reviewWhat information helps scope the work fastest?
Device description, contact type and duration, materials, current documents, and the target pathway. With that, the next step is usually clear quickly.
Send a project briefHow quickly will we know the right next step?
Usually once the device context and current file state are reviewed, it becomes clear whether the right move is a BEP, a BER review, a gap review, or a broader consulting scope.
Share the current file stateWhat if we are not sure whether we need a BEP, BER, or TRA?
That is common. The first job is often to classify the problem correctly so you do not spend time rewriting the wrong document or ordering the wrong next step.
Use a gap review to decideUseful starting points: the ISO 10993 strategy guide, the practical ISO 10993-1:2025 gap checklist, and the chemical characterization support page for chemistry-driven files.
Latest Insights
Expert articles and regulatory updates on ISO 10993, EU MDR, FDA, and selected India topics — written by a practising consultant, not a template library.
Biological Evaluation Plan (BEP) for Medical Devices
What a BEP must do under ISO 10993, what reviewers expect, and when BEP drafting, review, or broader file triage is the right next step.
Biological Evaluation Report (BER) for Medical Devices
What a BER must do under ISO 10993, where reports usually fail, and when drafting or review support is the right next step.
Biocompatibility Evaluation for Medical Devices
What biocompatibility evaluation really means under ISO 10993, where BEP and BER fit, when TRA matters, and why testing alone is not the whole biological-safety argument.
Implantable Device Biocompatibility Under ISO 10993
Why long-term implants need a different biological evaluation mindset, and where chemistry, sterilization, and finished-device logic become much harder to defend.
FDA Chemical Analysis Draft Guidance for ISO 10993-18
What FDA's still-draft chemical analysis guidance means for ISO 10993-18, TRA, and chemistry-driven 510(k) files.
EUDAMED Becomes Mandatory on 28 May 2026: What EU MDR Teams Should Recheck
What the EUDAMED milestone changes for actor data, device registration, certificates, and document-control readiness.
Preparing a Biological Evaluation?
Request a Scoping Review.
Whether you're preparing an initial BEP, responding to a notified body query, or updating legacy documentation to ISO 10993-1:2025, send the project context and I will outline the likely scope, priorities, and next step before any engagement.
I respond within 24 hours on business days